Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06799195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Study acronym: PTCYGVHD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 12 words Secondary endpoints: details revised at 16 of 16 entries · Study description revised · Publications: details revised at 4 of 4 entries Show 3 more changesShow less
    • Secondary endpoints: details revised at 16 of 16 entries
    • Study description revised
    • Publications: details revised at 4 of 4 entries
  2. Site contact updatedv5
  3. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Feb 2031 to Apr 2031 · Start date changed from estimate of May 2025 to Jun 23, 2025 · Site details revisedv4 Show 3 more changesShow less
    • Primary completion date: Feb 2031 to Apr 2031
    • Start date changed from estimate of May 2025 to Jun 23, 2025
    • Site details revised
  4. Re-verified, no change to tracked fieldsv3
  5. Primary endpoint revised Secondary endpoints revised (16)v2 Show 1 more changeShow less
    • Secondary endpoints revised (16)

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Trial Details
NCT Number NCT06799195
Lead Sponsor University of Nebraska
Conditions Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov